SGLT2 Inhibitor
Canagliflozin for Diabetic Kidney Disease
This trial is testing Canagliflozin, a medication that helps remove sugar from the body through urine, on adults with Type 2 diabetes and early kidney disease. The goal is to see if it can protect their kidney function by lowering blood sugar levels.
Glucagon-like peptide-1 (GLP-1) receptor agonist
Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
"This trial aims to see how semaglutide affects kidney function and oxygen levels in people with type 1 diabetes. It will also look at how semaglutide impacts blood sugar levels and safety
NAD+ precursor
NAD Augmentation for Diabetic Kidney Disease
This trial is testing whether NMN, a compound that may improve cell function, can help older adults with type 2 diabetes and high urine protein levels. The goal is to see if NMN can reduce kidney damage by improving cell energy production. Participants will receive NMN to compare the effects.
Popular Filters
Trials for Diabetic Kidney Disease Patients
SGLT2 Inhibitor
Sotagliflozin for Diabetic Kidney Disease
This trial aims to test the effects of a new drug called SOTA on kidney function in people with type 1 diabetes and moderate to advanced kidney disease. Previous studies have shown that SOTA can increase
Behavioural Intervention
Basic Needs Navigation for Diabetic Kidney Disease
This trial will test a basic needs navigation intervention to see if it can help low-income African Americans with diabetic kidney disease who are experiencing multidimensional adversity. The study will look at feasibility, clinical outcomes, self-care behaviors, and quality of life.
Biguanide
Metformin + Automated Insulin Delivery for Type 1 Diabetes
This trial tests a device that automatically adjusts insulin levels and a medication called metformin in young people with type 1 diabetes. The goal is to see if this combination can better manage blood sugar and improve heart and kidney health. The use of metformin along with insulin therapy has been suggested as a means of improving diabetes control and alleviating weight gain in type 1 diabetes.
Fibrate
Fenofibrate for Type 1 Diabetes
This trial is to test whether the generic drug fenofibrate can prevent kidney damage in people with type 1 diabetes. 40 participants will be enrolled and given either fenofibrate or placebo for 18 months. Kidney function will be measured at the beginning and end of the study.
Trials for DKD Patients
SGLT2 Inhibitor
Sotagliflozin for Diabetic Kidney Disease
This trial aims to test the effects of a new drug called SOTA on kidney function in people with type 1 diabetes and moderate to advanced kidney disease. Previous studies have shown that SOTA can increase
Behavioural Intervention
Basic Needs Navigation for Diabetic Kidney Disease
This trial will test a basic needs navigation intervention to see if it can help low-income African Americans with diabetic kidney disease who are experiencing multidimensional adversity. The study will look at feasibility, clinical outcomes, self-care behaviors, and quality of life.
Biguanide
Metformin + Automated Insulin Delivery for Type 1 Diabetes
This trial tests a device that automatically adjusts insulin levels and a medication called metformin in young people with type 1 diabetes. The goal is to see if this combination can better manage blood sugar and improve heart and kidney health. The use of metformin along with insulin therapy has been suggested as a means of improving diabetes control and alleviating weight gain in type 1 diabetes.
Fibrate
Fenofibrate for Type 1 Diabetes
This trial is to test whether the generic drug fenofibrate can prevent kidney damage in people with type 1 diabetes. 40 participants will be enrolled and given either fenofibrate or placebo for 18 months. Kidney function will be measured at the beginning and end of the study.
Trials With No Placebo
SGLT2 Inhibitor
Combo Diabetes Drug for Type 2 Diabetes
This trial is designed to compare rates of the total number of cardiovascular, kidney, and death events among three alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD.
Behavioural Intervention
Basic Needs Navigation for Diabetic Kidney Disease
This trial will test a basic needs navigation intervention to see if it can help low-income African Americans with diabetic kidney disease who are experiencing multidimensional adversity. The study will look at feasibility, clinical outcomes, self-care behaviors, and quality of life.
Mesenchymal Stem Cell Therapy
Stem Cell Therapy for Chronic Kidney Disease
This trial is testing if using donor stem cells is safe and tolerable for people with chronic kidney disease. The stem cells might help repair their damaged kidneys. Stem cell therapy has shown potential in treating kidney diseases and aiding in kidney regeneration.
Behavioural Intervention
Exercise Program for Chronic Kidney Disease
This trial is studying how well a combined resistance training and aerobic exercise program works compared to a health education program in improving physical function in people with kidney dysfunction.
Genetic Test for Cardiorenal Complications in Type 2 Diabetes
"This trial aims to see if a genetic risk prediction test can help patients with Type 2 Diabetes avoid heart and kidney complications. Patients will be monitored over 18 months to see if knowing their risk helps
View More Related Trials
Frequently Asked Questions
Introduction to diabetic nephropathy
What are the top hospitals conducting diabetic nephropathy research?
In the realm of diabetic nephropathy, several top hospitals are leading the charge in clinical trials and research. Milwaukee's Medical College of Wisconsin is actively conducting one trial focused on this condition, with a total of three trials to their credit thus far. Their dedication to advancing understanding and treatment options for diabetic nephropathy became evident when they recorded their first trial in 2022. Similarly, in Boston, the renowned Joslin Diabetes Center has not only undertaken one active clinical trial but also boasts an impressive history of five past trials related to diabetic nephropathy since embarking on their pioneering investigation back in 1993.
Further contributing to the fight against this complex condition is the Brehm Center for Diabetes Research at the University of Michigan in Ann Arbor. With one ongoing trial underway and three previous investigations under its belt, this institution has been making significant strides since initiating its initial diabetic nephropathy study in 2014. In Burlington's Lahey Hospital and Medical Center, researchers are currently engaged in an active trial concerning diabetic nephropathy while marking their first recorded endeavor into exploring this area as recently as 2022.
Finally, SUNY Upstate Medical University located in Syracuse presents another vital player within this field by conducting one current clinical trial for diabetic nephropathy alongside three earlier studies conducted since launching their inaugural investigation back in 2014.
These hospitals' commitment to studying and treating complications arising from diabetes serves as a beacon of hope for patients suffering from conditions like diabetic nephropathy. Through innovative research practices and determined medical teams across various regions, we inch ever closer towards better management strategies and improved patient outcomes.
Which are the best cities for diabetic nephropathy clinical trials?
When it comes to clinical trials for diabetic nephropathy, several cities have emerged as leaders in research. Milwaukee, Wisconsin; Boston, Massachusetts; Ann Arbor, Michigan; Burlington, Massachusetts; and Syracuse, New york each offer 1 active trial studying treatments like Intervention Group or Fenofibrate. These cities provide individuals with access to cutting-edge research opportunities aimed at advancing the understanding and management of diabetic nephropathy.
Which are the top treatments for diabetic nephropathy being explored in clinical trials?
Clinical trials are exploring various treatments for diabetic nephropathy, a complication of diabetes that affects the kidneys. Two standout options being investigated include fenofibrate and allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion. Fenofibrate, introduced in 2016, is currently under investigation in one active trial specifically targeting diabetic nephropathy among its three total trials. Another promising treatment is the single infusion of allogeneic adipose-derived MSCs, which entered the clinical trial scene in 2021 and is being studied in one ongoing trial dedicated to diabetic nephropathy. These innovative approaches hold significant potential for improving outcomes for individuals with this condition.
What are the most recent clinical trials for diabetic nephropathy?
Recent clinical trials offer promising advancements in the treatment of diabetic nephropathy, a serious complication of diabetes affecting the kidneys. One notable trial focuses on the use of fenofibrate, which has shown potential benefits in managing this condition during its Phase 2 study. Additionally, allogeneic adipose-derived mesenchymal stem cells (MSC) have demonstrated promise as a single infusion therapy for diabetic nephropathy patients in their Phase 1 trial. Furthermore, ongoing investigations are exploring various approaches to better understand and address this condition's complexities through combined Phase 1 and Phase 2 studies. Although earlier trials with thiamine and isolated pancreas transplants were conducted several years ago, they provide valuable insights into potential treatments for diabetic nephropathy. These recent clinical trials offer hope for improved outcomes and quality of life among individuals affected by this challenging disease.
What diabetic nephropathy clinical trials were recently completed?
Several noteworthy clinical trials investigating treatments for diabetic nephropathy have recently concluded, offering hope for patients with this condition. In April 2021, Boehringer Ingelheim completed a trial examining the efficacy of BI 685509 in managing diabetic nephropathy. Additionally, CSL Behring's study on CSL346 was finalized in September 2020 and AstraZeneca wrapped up their MEDI3506 trial in November 2019. These significant milestones represent important strides forward in our understanding and treatment of diabetic nephropathy, potentially leading to improved outcomes for those affected by this complication of diabetes.